HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.

AbstractINTRODUCTION:
The aim of the study was to evaluate the uptake of [(18)F]-1-deoxy-1-fluoro-scyllo-inositol ([(18)F]-scyllo-inositol) in human breast cancer (BC) and glioma xenografts, as well as in inflammatory tissue, in immunocompromised mice. Studies of [(18)F]-2-fluoro-2-deoxy-d-glucose ([(18)F]-FDG) under the same conditions were also performed.
METHODS:
Radiosynthesis of [(18)F]-scyllo-inositol was automated using a commercial synthesis module. Tumour, inflammation and normal tissue uptakes were evaluated by biodistribution studies and positron emission tomography (PET) imaging using [(18)F]-scyllo-inositol and [(18)F]-FDG in mice bearing subcutaneous MDA-MB-231, MCF-7 and MDA-MB-361 human BC xenografts, intracranial U-87 MG glioma xenografts and turpentine-induced inflammation.
RESULTS:
The radiosynthesis of [(18)F]-scyllo-inositol was automated with good radiochemical yields (24.6%±3.3%, uncorrected for decay, 65±2 min, n=5) and high specific activities (≥195 GBq/μmol at end of synthesis). Uptake of [(18)F]-scyllo-inositol was greatest in MDA-MB-231 BC tumours and was comparable to that of [(18)F]-FDG (4.6±0.5 vs. 5.5±2.1 %ID/g, respectively; P=.40), but was marginally lower in MDA-MB-361 and MCF-7 xenografts. Uptake of [(18)F]-scyllo-inositol in inflammation was lower than [(18)F]-FDG. While uptake of [(18)F]-scyllo-inositol in intracranial U-87 MG xenografts was significantly lower than [(18)F]-FDG, the tumour-to-brain ratio was significantly higher (10.6±2.5 vs. 2.1±0.6; P=.001).
CONCLUSIONS:
Consistent with biodistribution studies, uptake of [(18)F]-scyllo-inositol was successfully visualized by PET imaging in human BC and glioma xenografts, with lower accumulation in inflammatory tissue than [(18)F]-FDG. The tumour-to-brain ratio of [(18)F]-scyllo-inositol was also significantly higher than that of [(18)F]-FDG for visualizing intracranial glioma xenografts in NOD SCID mice, giving a better contrast.
AuthorsKristin McLarty, Matthew D Moran, Deborah A Scollard, Conrad Chan, Nesrin Sabha, Joydeep Mukherjee, Abhijit Guha, JoAnne McLaurin, Mark Nitz, Sylvain Houle, Alan A Wilson, Raymond M Reilly, Neil Vasdev
JournalNuclear medicine and biology (Nucl Med Biol) Vol. 38 Issue 7 Pg. 953-9 (Oct 2011) ISSN: 1872-9614 [Electronic] United States
PMID21982567 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Elsevier Inc. All rights reserved.
Chemical References
  • (18F)-1-deoxy-1-fluoro-scyllo-inositol
  • Fluorodeoxyglucose F18
  • Inositol
Topics
  • Animals
  • Biological Transport
  • Brain Neoplasms (diagnostic imaging, metabolism, pathology)
  • Breast Neoplasms (diagnostic imaging, metabolism, pathology)
  • Cell Line, Tumor
  • Female
  • Fluorodeoxyglucose F18 (chemistry, metabolism)
  • Humans
  • Inflammation (diagnostic imaging, metabolism, pathology)
  • Inositol (analogs & derivatives, chemistry, metabolism)
  • Male
  • Mice
  • Mice, Inbred NOD
  • Mice, Nude
  • Mice, SCID
  • Neoplasm Transplantation
  • Positron-Emission Tomography (methods)
  • Radiochemistry
  • Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: